Your browser doesn't support javascript.
loading
Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts.
Ambady, Prakash; Wu, Yingjen Jeffrey; Kersch, Cymon N; Walker, Joshua M; Holland, Samantha; Muldoon, Leslie L; Neuwelt, Edward A.
Afiliação
  • Ambady P; Department of Neurology, Oregon Health and Sciences University, Portland, OR, USA. ambady@ohsu.edu.
  • Wu YJ; Department of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
  • Kersch CN; Department of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
  • Walker JM; Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
  • Holland S; Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA.
  • Muldoon LL; Department of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
  • Neuwelt EA; Department of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
Cancer Gene Ther ; 29(5): 533-542, 2022 05.
Article em En | MEDLINE | ID: mdl-33850305
ABSTRACT
Overexpression of O6-methylguanine DNA methyltransferase (MGMT) contributes to resistance to chemo-radiation therapy (CRT) in brain tumors. We previously demonstrated that non-ablative radiation improved delivery of anti-MGMT morpholino oligonucleotides (AMONs) to reduce MGMT levels in subcutaneous tumor xenografts. We evaluate this approach to enhance CRT efficacy in rat brain tumor xenograft models. The impact of radiation on targeted delivery was evaluated using fluorescent oligonucleotides (f-ON). In vitro, f-ON was localized to clathrin-coated vesicles, endosomes, and lysosomes using confocal microscopy in T98G glioma cells. In vivo, fluorescence was detected in pre-radiated, but not non-radiated Long Evans (non-tumor bearing) rat brains. Cranial radiation (2 Gy) followed by AMONs (intravenous, 10.5 mg/kg) reduced MGMT expression by 50% in both orthotopic cerebellar D283 medulloblastoma and intracerebral H460 non-small cell lung carcinoma (NSCLC) xenograft models. To evaluate the efficacy, AMONs concurrent with CRT (2 Gy radiation plus oral 20 mg/kg temozolomide ×4 days) reduced tumor volumes in the medulloblastoma model (p = 0.012), and a similar trend was found in the NSCLC brain metastasis model. We provide proof of concept for the use of non-ablative radiation to guide and enhance the delivery of morpholino oligonucleotides into brain tumor xenograft models to reduce MGMT levels and improve CRT efficacy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias Cerebelares / Meduloblastoma Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias Cerebelares / Meduloblastoma Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article